LinkedIn Profile

Access Mirimus historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:mirimus 2415928 Dec 3rd, 2020 12:00AM Mirimus, Inc. 625 21.00 Open Biotechnology Dec 3rd, 2020 11:42AM Dec 3rd, 2020 11:42AM At Mirimus, our mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself. The cost of developing drugs has continued to skyrocket, mostly attributable to the number of drug compounds that fail in late-stage clinical trials either due to lack of efficacy or unpredicted toxicities that impede their use in humans. Thus, the need for more innovative approaches to perform proof-of-mechanism, efficacy and safety studies early on within the discovery pipeline has never been greater. Mirimus’ advanced RNAi technology platform enables potent reversible gene silencing in vivo, and has been shown to effectively mimic drug therapy, enabling pharmaceutical companies the ability to evaluate specific gene targets or combination targets prior to expensive drug development. We also aim to remain at the cutting edge of biomedical research, incorporating the latest emerging technologies, including CRISPR/Cas9 genome editing, and engineering the most advanced research tools for high impact screening assays and sophisticated disease model creation. With our rapid and cost-effective approaches, we have pioneered the way for systematic production of large cohorts of preclinical subjects, designed to more precisely model human disease and ready to evaluate therapeutic potential of specific gene targets. By synergizing CRISPR/Cas9 and RNAi technologies, our next generation CRISPR/Cas9-RNAi mouse models will serve to transform preclinical drug discovery research and drive the development of effective and safe candidate therapies to combat human disease. Open Transgenic mice, RNA interference, Drug discovery tools, shRNA technology, COVID-19 Open 760 Parkside Ave Brooklyn New York US 11226 Mirimus Health Care Pharmaceuticals & Biotechnology
private:mirimus 2415928 Dec 2nd, 2020 12:00AM Mirimus, Inc. 623 21.00 Open Biotechnology Dec 2nd, 2020 02:02PM Dec 2nd, 2020 02:02PM At Mirimus, our mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself. The cost of developing drugs has continued to skyrocket, mostly attributable to the number of drug compounds that fail in late-stage clinical trials either due to lack of efficacy or unpredicted toxicities that impede their use in humans. Thus, the need for more innovative approaches to perform proof-of-mechanism, efficacy and safety studies early on within the discovery pipeline has never been greater. Mirimus’ advanced RNAi technology platform enables potent reversible gene silencing in vivo, and has been shown to effectively mimic drug therapy, enabling pharmaceutical companies the ability to evaluate specific gene targets or combination targets prior to expensive drug development. We also aim to remain at the cutting edge of biomedical research, incorporating the latest emerging technologies, including CRISPR/Cas9 genome editing, and engineering the most advanced research tools for high impact screening assays and sophisticated disease model creation. With our rapid and cost-effective approaches, we have pioneered the way for systematic production of large cohorts of preclinical subjects, designed to more precisely model human disease and ready to evaluate therapeutic potential of specific gene targets. By synergizing CRISPR/Cas9 and RNAi technologies, our next generation CRISPR/Cas9-RNAi mouse models will serve to transform preclinical drug discovery research and drive the development of effective and safe candidate therapies to combat human disease. Open Transgenic mice, RNA interference, Drug discovery tools, shRNA technology, COVID-19 Open 760 Parkside Ave Brooklyn New York US 11226 Mirimus Health Care Pharmaceuticals & Biotechnology
private:mirimus 2415928 Dec 1st, 2020 12:00AM Mirimus, Inc. 620 21.00 Open Biotechnology Dec 1st, 2020 01:33PM Dec 1st, 2020 01:33PM At Mirimus, our mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself. The cost of developing drugs has continued to skyrocket, mostly attributable to the number of drug compounds that fail in late-stage clinical trials either due to lack of efficacy or unpredicted toxicities that impede their use in humans. Thus, the need for more innovative approaches to perform proof-of-mechanism, efficacy and safety studies early on within the discovery pipeline has never been greater. Mirimus’ advanced RNAi technology platform enables potent reversible gene silencing in vivo, and has been shown to effectively mimic drug therapy, enabling pharmaceutical companies the ability to evaluate specific gene targets or combination targets prior to expensive drug development. We also aim to remain at the cutting edge of biomedical research, incorporating the latest emerging technologies, including CRISPR/Cas9 genome editing, and engineering the most advanced research tools for high impact screening assays and sophisticated disease model creation. With our rapid and cost-effective approaches, we have pioneered the way for systematic production of large cohorts of preclinical subjects, designed to more precisely model human disease and ready to evaluate therapeutic potential of specific gene targets. By synergizing CRISPR/Cas9 and RNAi technologies, our next generation CRISPR/Cas9-RNAi mouse models will serve to transform preclinical drug discovery research and drive the development of effective and safe candidate therapies to combat human disease. Open Transgenic mice, RNA interference, Drug discovery tools, shRNA technology, COVID-19 Open 760 Parkside Ave Brooklyn New York US 11226 Mirimus Health Care Pharmaceuticals & Biotechnology
private:mirimus 2415928 Nov 30th, 2020 12:00AM Mirimus, Inc. 618 21.00 Open Biotechnology Nov 29th, 2020 07:38PM Nov 30th, 2020 02:25PM At Mirimus, our mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself. The cost of developing drugs has continued to skyrocket, mostly attributable to the number of drug compounds that fail in late-stage clinical trials either due to lack of efficacy or unpredicted toxicities that impede their use in humans. Thus, the need for more innovative approaches to perform proof-of-mechanism, efficacy and safety studies early on within the discovery pipeline has never been greater. Mirimus’ advanced RNAi technology platform enables potent reversible gene silencing in vivo, and has been shown to effectively mimic drug therapy, enabling pharmaceutical companies the ability to evaluate specific gene targets or combination targets prior to expensive drug development. We also aim to remain at the cutting edge of biomedical research, incorporating the latest emerging technologies, including CRISPR/Cas9 genome editing, and engineering the most advanced research tools for high impact screening assays and sophisticated disease model creation. With our rapid and cost-effective approaches, we have pioneered the way for systematic production of large cohorts of preclinical subjects, designed to more precisely model human disease and ready to evaluate therapeutic potential of specific gene targets. By synergizing CRISPR/Cas9 and RNAi technologies, our next generation CRISPR/Cas9-RNAi mouse models will serve to transform preclinical drug discovery research and drive the development of effective and safe candidate therapies to combat human disease. Open Transgenic mice, RNA interference, Drug discovery tools, shRNA technology, COVID-19 Open 760 Parkside Ave Brooklyn New York US 11226 Mirimus Health Care Pharmaceuticals & Biotechnology
private:mirimus 2415928 Nov 28th, 2020 12:00AM Mirimus, Inc. 615 21.00 Open Biotechnology Nov 28th, 2020 03:13PM Nov 28th, 2020 03:13PM At Mirimus, our mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself. The cost of developing drugs has continued to skyrocket, mostly attributable to the number of drug compounds that fail in late-stage clinical trials either due to lack of efficacy or unpredicted toxicities that impede their use in humans. Thus, the need for more innovative approaches to perform proof-of-mechanism, efficacy and safety studies early on within the discovery pipeline has never been greater. Mirimus’ advanced RNAi technology platform enables potent reversible gene silencing in vivo, and has been shown to effectively mimic drug therapy, enabling pharmaceutical companies the ability to evaluate specific gene targets or combination targets prior to expensive drug development. We also aim to remain at the cutting edge of biomedical research, incorporating the latest emerging technologies, including CRISPR/Cas9 genome editing, and engineering the most advanced research tools for high impact screening assays and sophisticated disease model creation. With our rapid and cost-effective approaches, we have pioneered the way for systematic production of large cohorts of preclinical subjects, designed to more precisely model human disease and ready to evaluate therapeutic potential of specific gene targets. By synergizing CRISPR/Cas9 and RNAi technologies, our next generation CRISPR/Cas9-RNAi mouse models will serve to transform preclinical drug discovery research and drive the development of effective and safe candidate therapies to combat human disease. Open Transgenic mice, RNA interference, Drug discovery tools, shRNA technology, COVID-19 Open 760 Parkside Ave Brooklyn New York US 11226 Mirimus Health Care Pharmaceuticals & Biotechnology
private:mirimus 2415928 Nov 27th, 2020 12:00AM Mirimus, Inc. 610 21.00 Open Biotechnology Nov 27th, 2020 11:38AM Nov 27th, 2020 11:38AM At Mirimus, our mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself. The cost of developing drugs has continued to skyrocket, mostly attributable to the number of drug compounds that fail in late-stage clinical trials either due to lack of efficacy or unpredicted toxicities that impede their use in humans. Thus, the need for more innovative approaches to perform proof-of-mechanism, efficacy and safety studies early on within the discovery pipeline has never been greater. Mirimus’ advanced RNAi technology platform enables potent reversible gene silencing in vivo, and has been shown to effectively mimic drug therapy, enabling pharmaceutical companies the ability to evaluate specific gene targets or combination targets prior to expensive drug development. We also aim to remain at the cutting edge of biomedical research, incorporating the latest emerging technologies, including CRISPR/Cas9 genome editing, and engineering the most advanced research tools for high impact screening assays and sophisticated disease model creation. With our rapid and cost-effective approaches, we have pioneered the way for systematic production of large cohorts of preclinical subjects, designed to more precisely model human disease and ready to evaluate therapeutic potential of specific gene targets. By synergizing CRISPR/Cas9 and RNAi technologies, our next generation CRISPR/Cas9-RNAi mouse models will serve to transform preclinical drug discovery research and drive the development of effective and safe candidate therapies to combat human disease. Open Transgenic mice, RNA interference, Drug discovery tools, shRNA technology, COVID-19 Open 760 Parkside Ave Brooklyn New York US 11226 Mirimus Health Care Pharmaceuticals & Biotechnology
private:mirimus 2415928 Nov 26th, 2020 12:00AM Mirimus, Inc. 607 21.00 Open Biotechnology Nov 26th, 2020 12:37PM Nov 26th, 2020 12:37PM At Mirimus, our mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself. The cost of developing drugs has continued to skyrocket, mostly attributable to the number of drug compounds that fail in late-stage clinical trials either due to lack of efficacy or unpredicted toxicities that impede their use in humans. Thus, the need for more innovative approaches to perform proof-of-mechanism, efficacy and safety studies early on within the discovery pipeline has never been greater. Mirimus’ advanced RNAi technology platform enables potent reversible gene silencing in vivo, and has been shown to effectively mimic drug therapy, enabling pharmaceutical companies the ability to evaluate specific gene targets or combination targets prior to expensive drug development. We also aim to remain at the cutting edge of biomedical research, incorporating the latest emerging technologies, including CRISPR/Cas9 genome editing, and engineering the most advanced research tools for high impact screening assays and sophisticated disease model creation. With our rapid and cost-effective approaches, we have pioneered the way for systematic production of large cohorts of preclinical subjects, designed to more precisely model human disease and ready to evaluate therapeutic potential of specific gene targets. By synergizing CRISPR/Cas9 and RNAi technologies, our next generation CRISPR/Cas9-RNAi mouse models will serve to transform preclinical drug discovery research and drive the development of effective and safe candidate therapies to combat human disease. Open Transgenic mice, RNA interference, Drug discovery tools, shRNA technology, COVID-19 Open 760 Parkside Ave Brooklyn New York US 11226 Mirimus Health Care Pharmaceuticals & Biotechnology
private:mirimus 2415928 Nov 25th, 2020 12:00AM Mirimus, Inc. 606 21.00 Open Biotechnology Nov 25th, 2020 06:04PM Nov 25th, 2020 06:04PM At Mirimus, our mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself. The cost of developing drugs has continued to skyrocket, mostly attributable to the number of drug compounds that fail in late-stage clinical trials either due to lack of efficacy or unpredicted toxicities that impede their use in humans. Thus, the need for more innovative approaches to perform proof-of-mechanism, efficacy and safety studies early on within the discovery pipeline has never been greater. Mirimus’ advanced RNAi technology platform enables potent reversible gene silencing in vivo, and has been shown to effectively mimic drug therapy, enabling pharmaceutical companies the ability to evaluate specific gene targets or combination targets prior to expensive drug development. We also aim to remain at the cutting edge of biomedical research, incorporating the latest emerging technologies, including CRISPR/Cas9 genome editing, and engineering the most advanced research tools for high impact screening assays and sophisticated disease model creation. With our rapid and cost-effective approaches, we have pioneered the way for systematic production of large cohorts of preclinical subjects, designed to more precisely model human disease and ready to evaluate therapeutic potential of specific gene targets. By synergizing CRISPR/Cas9 and RNAi technologies, our next generation CRISPR/Cas9-RNAi mouse models will serve to transform preclinical drug discovery research and drive the development of effective and safe candidate therapies to combat human disease. Open Transgenic mice, RNA interference, Drug discovery tools, shRNA technology, COVID-19 Open 760 Parkside Ave Brooklyn New York US 11226 Mirimus Health Care Pharmaceuticals & Biotechnology
private:mirimus 2415928 Nov 24th, 2020 12:00AM Mirimus, Inc. 606 20.00 Open Biotechnology Nov 24th, 2020 01:21PM Nov 24th, 2020 01:21PM At Mirimus, our mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself. The cost of developing drugs has continued to skyrocket, mostly attributable to the number of drug compounds that fail in late-stage clinical trials either due to lack of efficacy or unpredicted toxicities that impede their use in humans. Thus, the need for more innovative approaches to perform proof-of-mechanism, efficacy and safety studies early on within the discovery pipeline has never been greater. Mirimus’ advanced RNAi technology platform enables potent reversible gene silencing in vivo, and has been shown to effectively mimic drug therapy, enabling pharmaceutical companies the ability to evaluate specific gene targets or combination targets prior to expensive drug development. We also aim to remain at the cutting edge of biomedical research, incorporating the latest emerging technologies, including CRISPR/Cas9 genome editing, and engineering the most advanced research tools for high impact screening assays and sophisticated disease model creation. With our rapid and cost-effective approaches, we have pioneered the way for systematic production of large cohorts of preclinical subjects, designed to more precisely model human disease and ready to evaluate therapeutic potential of specific gene targets. By synergizing CRISPR/Cas9 and RNAi technologies, our next generation CRISPR/Cas9-RNAi mouse models will serve to transform preclinical drug discovery research and drive the development of effective and safe candidate therapies to combat human disease. Open Transgenic mice, RNA interference, Drug discovery tools, shRNA technology, COVID-19 Open 760 Parkside Ave Brooklyn New York US 11226 Mirimus Health Care Pharmaceuticals & Biotechnology
private:mirimus 2415928 Nov 23rd, 2020 12:00AM Mirimus, Inc. 602 20.00 Open Biotechnology Nov 23rd, 2020 03:23PM Nov 23rd, 2020 03:23PM At Mirimus, our mission is to change the paradigm of the current drug discovery process by developing superior preclinical RNA interference (RNAi) animal models that can predict toxicities of potential drug therapies without the actual drug itself. The cost of developing drugs has continued to skyrocket, mostly attributable to the number of drug compounds that fail in late-stage clinical trials either due to lack of efficacy or unpredicted toxicities that impede their use in humans. Thus, the need for more innovative approaches to perform proof-of-mechanism, efficacy and safety studies early on within the discovery pipeline has never been greater. Mirimus’ advanced RNAi technology platform enables potent reversible gene silencing in vivo, and has been shown to effectively mimic drug therapy, enabling pharmaceutical companies the ability to evaluate specific gene targets or combination targets prior to expensive drug development. We also aim to remain at the cutting edge of biomedical research, incorporating the latest emerging technologies, including CRISPR/Cas9 genome editing, and engineering the most advanced research tools for high impact screening assays and sophisticated disease model creation. With our rapid and cost-effective approaches, we have pioneered the way for systematic production of large cohorts of preclinical subjects, designed to more precisely model human disease and ready to evaluate therapeutic potential of specific gene targets. By synergizing CRISPR/Cas9 and RNAi technologies, our next generation CRISPR/Cas9-RNAi mouse models will serve to transform preclinical drug discovery research and drive the development of effective and safe candidate therapies to combat human disease. Open Transgenic mice, RNA interference, Drug discovery tools, shRNA technology, COVID-19 Open 760 Parkside Ave Brooklyn New York US 11226 Mirimus Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.